癌变·畸变·突变
癌變·畸變·突變
암변·기변·돌변
CARCINOGENSES,TERATOGENSIS AND MUTAGENESIS
2014年
5期
334-338
,共5页
甲基苄基亚硝胺%食管癌%癌前病变%β-catenin%Ser675位点%磷酸化
甲基芐基亞硝胺%食管癌%癌前病變%β-catenin%Ser675位點%燐痠化
갑기변기아초알%식관암%암전병변%β-catenin%Ser675위점%린산화
methyl benzyl nitrosamine%esophageal carcinoma%precancerous lesions%β-catenin%Ser675%phosphorylation
目的:探讨甲基苄基亚硝胺(MBNA)诱导食管癌前病变食管组织中-连环蛋白(-catenin)mRNA转录、蛋白表达及其Ser675位点磷酸化水平的变化。方法:Wistar大鼠按3.5 mg/kg皮下注射0.15% MBNA溶液,每周2次作为模型组,以同批次正常大鼠(皮下注射生理盐水)为对照组,每组8只,连续10周,于造模第10周处死2组大鼠,观察食管黏膜病理变化,采用定量PCR检测食管组织中β-catenin mRNA转录水平,Western blot检测β-catenin蛋白及其Ser675位点磷酸化蛋白表达水平,免疫组化检测β-catenin蛋白表达的定位情况。结果:MBNA诱导10周后模型组大鼠均可见食管黏膜粗糙,部分可见乳突瘤,食管黏膜病理学检查呈轻度不典型增生,且模型组大鼠食管组织中β-catenin mRNA转录水平(0.619±0.086)较正常组(1.000±0.235)降低(P<0.01);β-catenin蛋白表达水平(1.476±0.363)较正常组(1.000±0.496)升高(P<0.05);Ser675位点磷酸化β-catenin蛋白表达水平(2.150±0.469)较正常组(1.000±0.367)升高(P<0.01);免疫组化结果显示β-catenin定位表达于食管黏膜上皮细胞,且模型组中的表达较正常组增强。结论:β-catenin蛋白的异常表达及其Ser675位点磷酸化水平的升高与食管癌变的病理变化可能直接相关,可作为食管癌研究的靶点。癌ββ
目的:探討甲基芐基亞硝胺(MBNA)誘導食管癌前病變食管組織中-連環蛋白(-catenin)mRNA轉錄、蛋白錶達及其Ser675位點燐痠化水平的變化。方法:Wistar大鼠按3.5 mg/kg皮下註射0.15% MBNA溶液,每週2次作為模型組,以同批次正常大鼠(皮下註射生理鹽水)為對照組,每組8隻,連續10週,于造模第10週處死2組大鼠,觀察食管黏膜病理變化,採用定量PCR檢測食管組織中β-catenin mRNA轉錄水平,Western blot檢測β-catenin蛋白及其Ser675位點燐痠化蛋白錶達水平,免疫組化檢測β-catenin蛋白錶達的定位情況。結果:MBNA誘導10週後模型組大鼠均可見食管黏膜粗糙,部分可見乳突瘤,食管黏膜病理學檢查呈輕度不典型增生,且模型組大鼠食管組織中β-catenin mRNA轉錄水平(0.619±0.086)較正常組(1.000±0.235)降低(P<0.01);β-catenin蛋白錶達水平(1.476±0.363)較正常組(1.000±0.496)升高(P<0.05);Ser675位點燐痠化β-catenin蛋白錶達水平(2.150±0.469)較正常組(1.000±0.367)升高(P<0.01);免疫組化結果顯示β-catenin定位錶達于食管黏膜上皮細胞,且模型組中的錶達較正常組增彊。結論:β-catenin蛋白的異常錶達及其Ser675位點燐痠化水平的升高與食管癌變的病理變化可能直接相關,可作為食管癌研究的靶點。癌ββ
목적:탐토갑기변기아초알(MBNA)유도식관암전병변식관조직중-련배단백(-catenin)mRNA전록、단백표체급기Ser675위점린산화수평적변화。방법:Wistar대서안3.5 mg/kg피하주사0.15% MBNA용액,매주2차작위모형조,이동비차정상대서(피하주사생리염수)위대조조,매조8지,련속10주,우조모제10주처사2조대서,관찰식관점막병리변화,채용정량PCR검측식관조직중β-catenin mRNA전록수평,Western blot검측β-catenin단백급기Ser675위점린산화단백표체수평,면역조화검측β-catenin단백표체적정위정황。결과:MBNA유도10주후모형조대서균가견식관점막조조,부분가견유돌류,식관점막병이학검사정경도불전형증생,차모형조대서식관조직중β-catenin mRNA전록수평(0.619±0.086)교정상조(1.000±0.235)강저(P<0.01);β-catenin단백표체수평(1.476±0.363)교정상조(1.000±0.496)승고(P<0.05);Ser675위점린산화β-catenin단백표체수평(2.150±0.469)교정상조(1.000±0.367)승고(P<0.01);면역조화결과현시β-catenin정위표체우식관점막상피세포,차모형조중적표체교정상조증강。결론:β-catenin단백적이상표체급기Ser675위점린산화수평적승고여식관암변적병리변화가능직접상관,가작위식관암연구적파점。암ββ
OBJECTIVE: To find the changes ofβ-catenin and phosphorylatedβ-catenin (p-β-catenin) Ser675 in esophageal precancerous lesions in Wistar rats induced by methyl benzyl nitrosamine (MBNA).METHODS: Wistar rats received MBNA injections at dose of 3.5 mg/kg 2 times per week. At 10 weeks,the pathological changes of esophageal mucosa were examined.β-catenin mRNA level was measured by quantitative real-time PCR and the expressions ofβ-catenin protein and p-β-catenin(Ser675) were evaluated by Western blot. The location ofβ-catenin was detected by immunohistochemistry.RESULTS:Compared with normal group,the level ofβ-catenin mRNA was significantly decreased,the levels ofβ-catenin and p-β-catenin (Ser675) protein were significantly increased in treated group.CONCLUSION:The elevated protein levels ofβ-catenin and p-β-catenin (Ser675) were related with esophageal precancerous lesions in Wistar rats induced by MBNA ,and could be considered as an indicator of esophageal carcinoma.